OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Kamdar on the TRANSCEND NHL 001 Trial of Liso-Cel in Relapsed/Refractory MCL

July 1st 2024

Manali Kamdar, MD, discusses the patient population included in the mantle cell lymphoma cohort of the phase 3 TRANSCEND NHL 001 trial.

Dr Garcia-Manero on the Impact of Luspatercept on Hematopoietic Lineages in Lower-Risk MDS

July 1st 2024

Guillermo Garcia-Manero, MD, discusses the safety and impact of luspatercept on hematopoetic lineages in transfusion-dependent lower-risk MDS.

Dr Jhaveri on the Implications of DESTINY-Breast06 for HR+/HER2-Low and -Ultralow Breast Cancer

July 1st 2024

Komal Jhaveri, MD, FACP, discusses the implications of the DESTINY-Breast06 trial for hormone receptor–positive, HER2-low and -ultralow breast cancer.

Dr Mouabbi on the Use of Ribociclib vs Abemaciclib in HR+/HER2– Breast Cancer

June 28th 2024

Jason Abdou Mouabbi, MD, discusses considerations for the use of ribociclib vs abemaciclib in patients with HR-positive, HER2-negative breast cancer.

Dr Gong on the Frontline Use of PARP Inhibitors in mCRPC

June 28th 2024

Jun Gong, MD, discusses the variety of PARP inhibitor–based frontline treatment regimens that are FDA approved for patients with mCRPC.

Dr Phillips on the Evolution of the MCL Treatment Paradigm

June 28th 2024

Tycel Phillips, MD, discusses the evolution of treatment for patients with mantle cell lymphoma.

Dr Wirth on the Full FDA Approval of Selpercatinib for Advanced RET Fusion+ Thyroid Cancer

June 28th 2024

Lori Wirth, MD, discusses the significance of the full FDA approval of selpercatinib for patients with advanced or metastatic RET fusion+ thyroid cancer.

Dr Franses on the Feasibility of Co-Inhibiting Angiogenesis and PD-1 Pathways in HCC

June 28th 2024

Joseph Franses, MD, PhD, debates whether targeting angiogenesis and the PD-1/PD-L1 pathway in hepatocellular carcinoma is always a reliable approach.

Dr Owonikoko on the Impact of the FDA Approval of Tarlatamab in ES-SCLC

June 28th 2024

Taofeek Owonikoko, MD, PhD, expands on the FDA approval of tarlatamab for patients with extensive-stage small cell lung cancer.

Dr Chao on the Association Between Broad-Spectrum Antibiotic Use and the Risk of Early-Onset CRC

June 28th 2024

Chun Chao, MS, PhD, discusses the impact of broad-spectrum antibiotic use on the risk of developing early-onset colorectal adenocarcinoma.

Dr Llombart-Cussac on Preventing Neutropenia and Diarrhea in HR+/HER2– Advanced Breast Cancer

June 28th 2024

Antonio Llombart-Cussac, MD, PhD, discusses preventing neutropenia and diarrhea with sacituzumab govitecan in HR+/HER2– advanced breast cancer.

Dr Kyriakopoulos on Evaluating Biomarkers and Disease Progression with CTC Analysis in CHAARTED2 trial

June 28th 2024

Christos Kyriakopoulos, MD discusses two correlative studies conducted within the CHAARTED2 trial.

Dr Pothuri on Real-World Treatment Patterns Per MMR/MSI Status in Endometrial Cancer

June 27th 2024

Bhavana Pothuri, MD, discusses real-world treatment patterns and outcomes in patients with advanced endometrial cancer according to MMR/MSI status.

Dr Fakih on OS Data for Sotorasib Plus Panitumumab in KRAS G12C+ mCRC

June 27th 2024

Marwan G. Fakih, MD, discusses data for sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.

Dr O'Shaughnessy on MammaPrint H1 vs H2 Status on 3-year RFS in HR+, HER2– Breast Cancer

June 27th 2024

Joyce O'Shaughnessy, MD, on the impact of MammaPrint H1 and H2 status on 3-year relapse-free survival in HR-positive, HER2-negative early breast cancer.

Dr Maakaron on Choosing Between Bispecific Antibodies and CAR T-Cell Therapy in DLBCL

June 27th 2024

Joseph Maakaron, MD, discusses factors that influence his decision to use bispecific antibodies or CAR T-cell therapy in patients with DLBCL.

Dr O'Malley on Updates in Gynecologic Oncology at the 2024 ASCO Annual Meeting

June 27th 2024

David M. O’Malley, MD, and Chandler H. Park, MD, FACP, discuss updates in gynecologic oncology at the 2024 ASCO Annual Meeting.

Dr Mohty on the Real-World Efficacy of Elranatamab in R/R Multiple Myeloma

June 27th 2024

Mohamad Mohty, MD, PhD, discusses the real-world efficacy of elranatamab in patients with relapsed/refractory multiple myeloma.

Dr Ramalingam on Updates in Lung Cancer Following the 2024 ASCO Annual Meeting

June 27th 2024

Suresh S. Ramalingam, MD, FACP, FASCO, and Chandler H. Park, MD, FACP, discuss updates in non–small cell lung cancer at the 2024 ASCO Annual Meeting.

Dr Gross on the Neoadjuvant Utility of Cemiplimab in CSCC

June 27th 2024

Neil D. Gross, MD, FACS, discusses the neoadjuvant use of cemiplimab in the treatment of patients with cutaneous squamous cell carcinoma.